Latest Major R&D Pipeline

Major R&D Pipeline

(As of November 7, 2023)

  • ●:Development progress from July 2023 onwards ○:Development progress from April 2023 onwards

Neurology

Dementia

*You can scroll to the left or right here

DiseaseStudyRegionDevelopment Stage
「Leqembi」(lecanemab/BAN2401) Treatment for Alzheimer’s disease / anti-Aβ protofibril antibody In-license (BioArctic AB) Injection Joint development with Biogen Inc.
Early Alzheimer’s disease 301 (Clarity AD) US Traditional approval
(July 2023)
Japan Approval (September 2023)
Europe Submission
(accepted: January 2023)
China Submission
(December 2022)
Asia (South Korea) Submission
(June 2023)
Preclinical Alzheimer’s disease 303 (AHEAD 3-45) Japan/US/Europe PⅢ
E2814 anti-MTBR tau antibody Collaboration (University College London) Injection
Alzheimer’s disease Tau Nexgen Japan/US/Europe PⅡ/Ⅲ
103 US/Europe PⅠ/Ⅱ
E2027 Treatment for dementia with Lewy bodies, Parkinson’s disease dementia / PDE9 inhibitor In-house Oral
Dementia with Lewy bodies, Parkinson’s disease dementia 203 US PⅡ
E2511 Synapse regenerant In-house Oral
Alzheimer’s disease - US PⅠ
E2025 In-house Injection
Alzheimer’s disease - US PⅠ

Neurological diseases other than dementia

*You can scroll to the left or right here

DiseaseStudyRegionDevelopment Stage
「Fycompa」(perampanel/E2007) Antiepileptic agent / AMPA receptor antagonist In-house Oral
Injection formulation (Additional Formulation) - Japan Submission
(August 2022)
Primary generalized tonic-clonic seizures (Additional Indication) 332 China Submission
(March 2023)
Lennox-Gastaut syndrome (Additional Indication) 338 Japan/US/Europe PⅢ
「Dayvigo」(lemborexant/E2006) Insomnia treatment / Orexin receptor antagonist In-house Oral
Insomnia disorder 311 China PⅢ
Irregular sleep-wake rhythm disorder and Alzheimer’s disease dementia (Additional Indication) 202 Japan/US PⅡ
lorcaserin/E2023 Treatment for Dravet syndrome / serotonin 2C receptor agonist In-license (Arena Pharmaceuticals) Oral
Dravet syndrome 304 US PⅢ
E2086 In-house Oral
Narcolepsy - US PⅠ
EA4017 In-house Oral
Chemotherapy-induced peripheral neuropathy (Development conducted by EA Pharma) - Japan PⅠ

Oncology

*You can scroll to the left or right here

DiseaseStudyRegionDevelopment Stage
「Lenvima/Kisplyx」(lenvatinib/E7080) Anticancer agent / kinase inhibitor In-house Oral
In combination with anti-PD-1 therapy pembrolizumab, joint development with Merck & Co., Inc., Rahway, NJ, USA, through an affiliate (Additional Indication)
Endometrial carcinoma / First-line LEAP-001 Japan/US/Europe/China PⅢ
Hepatocellular carcinoma (in combination with transcatheter arterial chemoembolization) / First-line LEAP-012 Japan/US/Europe/China PⅢ
Esophageal carcinoma (in combination with chemotherapy) / First-line LEAP-014 Japan/US/Europe/China PⅢ
Gastric cancer (in combination with chemotherapy) / First-line LEAP-015 Japan/US/Europe/China PⅢ
Melanoma / Second-line LEAP-004 US/Europe PⅡ
Selected solid tumors (Gastric cancer, colorectal cancer, glioblastoma, biliary tract cancers and pancreatic cancer) LEAP-005 US/Europe PⅡ
Head and neck cancer / Second-line LEAP-009 US/Europe PⅡ
In combination with anticancer agent everolimus, joint development with Merck & Co., Inc., Rahway, NJ, USA, through an affiliate (Additional Indication)
Renal cell carcinoma / First-line 307 Japan/US/Europe PⅢ
In combination with anti-PD-1 antibody nivolumab, joint development with Ono Pharmaceutical (Additional Indication)
Hepatocellular carcinoma - Japan PⅠ
「Halaven」(eribulin/E7389) Anticancer agent / microtubule dynamics inhibitor In-house Injection
Monotherapy (Additional Formulation)
Liposomal formulation - Japan/Europe PⅠ
In combination with anti-PD-1 antibody nivolumab, joint development with Ono Pharmaceutical (Additional Formulation)
Liposomal formulation 120 Japan PⅠ/Ⅱ
farletuzumab ecteribulin(FZEC)/MORAb-202 Anticancer agent / Folate receptor α targeted antibody drug conjugate In-house Injection Joint development with Bristol Myers Squibb
Non-small cell lung cancer 203 US/Europe PⅡ
Ovarian cancer, peritoneal cancer, fallopian tube cancer 205 Japan/US/Europe PⅡ
Solid tumors 201 US/Europe PⅠ/Ⅱ
Solid tumors - Japan PⅠ
E7386 Anticancer agent / CBP/β-catenin interaction inhibitor Collaboration (PRISM BioLab) Oral
Solid tumors (in combination with pembrolizumab) 201 Japan/US/Europe PⅠ/Ⅱ
Solid tumors - Japan/US/Europe PⅠ
Solid tumors (in combination with lenvatinib) - Japan/US/Europe PⅠ
tasurgratinib/E7090 Anticancer agent / FGFR1, FGFR2, FGFR3 inhibitor In-house Oral
Cholangiocarcinoma 201 Japan/China PⅡ
Breast cancer - Japan PⅠ
H3B-6545 Anticancer agent / ERα inhibitor In-house Oral
Breast cancer 101 US/Europe PⅠ/Ⅱ
Breast cancer (in combination with CDK4/6 inhibitor palbociclib) - US/Europe PⅠ
E7130 Collaboration (Harvard University) Injection
Solid tumors - Japan PⅠ
E7766 In-house Injection
Solid tumors - US/Europe PⅠ

Global Health

*You can scroll to the left or right here

DiseaseSponsor of studyRegionDevelopment Stage
fosravuconazole/E1224 Antifungal agent / ergosterol synthesis inhibitor In-house Oral
Eumycetoma
*Supported by GHIT fund
*Eisai is mainly responsible for non-clinical studies and the provision of the investigational drug.
DNDi・Mycetoma Research Center of the University of Khartoum Sudan PⅡb/Ⅲ
SJ733 Antimalarial agent / ATP4 inhibitor Co-development (University of Kentucky) Oral
Malaria
*Supported by GHIT fund
*Eisai is responsible for the provision of drug substance and formulation manufacturing
University of Kentucky Peru PⅡ
AWZ1066S Antifilarial agent / antiwolbachia mechanism Co-development (Liverpool School of Tropical Medicine) Oral
Lymphatic filariasis
*Supported by the GHIT Fund and Medical Research Council in the UK
*Eisai is responsible for the provision of drug substance and formulation manufacturing
Liverpool School of Tropical Medicine UK PⅠ

Gastrointestinal Disorders

*You can scroll to the left or right here

DiseaseStudyRegionDevelopment stage
MOVICOL/(AJG555) Chronic constipation treatment / polyethylene glycol preparation In-license (Norgine) Oral
Chronic constipation in children under 2 years of age (Additional Dosage and Administration) (Development conducted by EA Pharma) CT3 Japan PⅢ
AJM347 In-house Oral
Inflammatory bowel disease (Development conducted by EA Pharma) - Europe PⅠ
EA1080 In-house Oral
Inflammatory bowel disease (Development conducted by EA Pharma) - Europe PⅠ
EA3571 In-house Oral
Nonalcoholic steatohepatitis (Development conducted by EA Pharma) - Japan PⅠ

Other

*You can scroll to the left or right here

DiseaseStudyRegionDevelopment stage
dotinurad / FYU-981 Treatment for Hyperuricemia and Gout / selective URAT1 inhibitor In-license (FUJI YAKUHIN) Oral
Gout, hyperuricemia - Asia (Philippines) Submission (September 2023)
Gout 301 China PⅢ
E6742 Treatment for Systemic lupus erythematosus / TLR 7/8 inhibitor In-house Oral
Systemic lupus erythematosus 101 Japan PⅠ/Ⅱ
E8001 In house Injection
Rejection reaction associated with organ transplantation - Japan PⅠ